Unlock News Summary by Subscribing to iPick.ai Premium!
Ask anything related to MNOV. [ FAQ on what and how to ask] For non-MNOV questions, click the logo in the upper-right corner to return to the main page and ask there.
Unlock YouTube Video by Subscribing to iPick.ai Premium!
Not available
Address: 4275 Executive Square, Suite 300, La Jolla, CA, United States, 92037
Employees: 6
MediciNova, Inc., a biopharmaceutical company, focuses on developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs in the United States. It develops MN-166 (ibudilast), an oral anti-inflammatory and neuroprotective agent in Phase 2 clinical trial for treating neurological and other disorders, such as progressive multiple sclerosis, amyotrophic lateral sclerosis, chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, and glioblastoma, as well as prevention of acute respiratory distress syndrome. The company is also developing MN-001 (tipelukast), an orally bioavailable small molecule compound in Phase 2 clinical trial to treat fibrotic and other metabolic disorders, including nonalcoholic fatty liver disease and hypertriglycedemia. MediciNova, Inc. was incorporated in 2000 and is headquartered in La Jolla, California.
Co-Founder, President, CEO & Chairman
Senior VP, Chief Medical Officer & Director
Chief Business Officer
CFO & Principal Financial Officer
My Watchlist
